FSH response-dose can be predicted in ovulation induction for normogonadotropic XXXX .

@entity1 @entity249 @entity4082 @entity442 @entity1021
OBJECTIVE: To evaluate the ability of a prediction model to identify the individual @entity1021 dose of FSH for ovulation induction using a step-down regimen. DESIGN: Retrospective analysis of clinical data in an academic fertility unit. Fifty-six normogonadotropic @entity249 @entity1 who failed to ovulate or conceive with @entity4082 were included. They were treated with exogenous gonadotropins with a flexible @entity1021 dose for ovulation induction using a step-down regimen. The clinically applied @entity1021 dose of exogenous gonadotropins was compared with the calculated response-dose using a previously published prediction model. RESULTS: @entity1 were arbitrarily divided into three groups according to the day of the first decrease in gonadotropin dose: (a) early step-down (day 3 or earlier); (b) standard step-down (day 4 or later); (c) no step-down. These groups had average @entity1021 doses of 28.5 IU (group a) and 13 IU (group b) above the calculated response-dose, and 43 IU (group c) under the calculated response-dose. A significant correlation between day of first step-down and the difference between clinically applied and calculated response-dose was observed (P<0.0001, F-test for ANOVA). CONCLUSIONS: The @entity1 group with the best step-down profile for ovulation induction exhibited the closest match between the clinically applied and calculated @entity1021 dose of gonadotropins. Therefore, this study provides support for the concept that the individual effective FSH @entity1021 dose for gonadotropin induction of ovulation in @entity249 @entity1 can be predicted on the basis of initial screening characteristics, such as body mass index, @entity4082 resistance or failure, free @entity442 and FSH. This may result in more effective @entity1 treatment protocols, reduced complication rates and health-economic benefits.
